<DOC>
	<DOCNO>NCT01574846</DOCNO>
	<brief_summary>The aim non-interventional ( observational ) study document , collaboration establish urologist Scandinavia , experience gain routine use Vantas® treatment patient advanced prostate cancer . In observational study particular attention direct treatment duration , quality life patient physician acceptance medicinal product long-term therapy . Patient-based measurement parameter quality life degree satisfaction allow registration information extend beyond clinical parameter . The knowledge gather enable patient acceptance long-term therapy evaluate . Clinical outcome also document measure serum testosterone prostate specific antigen ( PSA ) level .</brief_summary>
	<brief_title>Prospective Multicentre Non-interventional Study VANTAS® Treatment Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male patient hormone treatment advanced prostate cancer indicate Age &gt; 18 year . Documented elevate PSA level . Contraindications Vantas® ( accordance Summary Product Characteristics ( SmPC ) )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>